Form 4: Syros Pharmaceuticals Director Akkaraju Srinivas Reports Stock Transactions

Director Akkaraju Srinivas reports the vesting of restricted stock units and subsequent sale of shares of Syros Pharmaceuticals common stock on June 1, 2024.

Summary

• On June 1, 2024, Akkaraju Srinivas, a director of Syros Pharmaceuticals, reported transactions involving the company's common stock.
• Specifically, 4,000 restricted stock units (RSUs) vested, each representing the right to receive one share of common stock.
• Simultaneously, 4,000 shares of common stock were disposed of.
• The vesting of the RSUs occurred on the first anniversary of the grant date.
• The transactions were reported on a Form 4 filing with the SEC.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership of shares.
• The filing provides transparency to stakeholders regarding insider trading activities.

Key Dates

Keywords

Syros Pharmaceuticals, Director, Akkaraju Srinivas, Form 4, SEC Filing, Restricted Stock Units, RSU, Common Stock, Vesting, Disposition